Ursula A. Matulonis, MD, is Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She is the first recipient of the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute. She is the Co-Leader of the Gynecologic Cancer Program within the Dana-Farber/Harvard Cancer Center and the co-PI of a P01 Program Project Grant entitled: Targeting Replication Stress and DNA Damage Response in Uterine Cancer.
Dr. Matulonis has led several PARP inhibitor, anti-angiogenic agent, immunotherapy, antibody drug conjugate, and combination targeted therapy trials for ovarian cancer in the United States and internationally. She is a member of the NCI Gynecologic Cancer Steering committee and the Global Expert Advisory Group on Ovarian Cancer. Dr. Matulonis serves as an Associate Editor of Gynecologic Oncology. She has received the Dana-Farber Dennis Thompson Compassionate Care Scholar award, the Lee M. Nadler “Extra Mile” Award, the Clearity Foundation award, the Zakim Award at Dana-Farber for patient advocacy, the Albany Medical College Alumni Association Distinguished Alumna Award and, in 2022, the Rosalind Franklin Prize for Excellence in Ovarian Cancer Research from the Ovarian Cancer Research Alliance.
After receiving her MD from Albany Medical College, she completed an internship and residency at the University of Pittsburgh, followed by a medical oncology fellowship at the Dana-Farber Cancer Institute in Boston, MA.